Immune checkpoint inhibitors (ICI), such as anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) antibodies, have improved the prognosis of patients with non-small cell lung cancer (NSCLC) [1]. Here, PDCD1 is linked to non-small cell lung carcinoma.